Literature DB >> 6218561

Susceptibility of moxalactam to beta-lactamase.

M H Richmond.   

Abstract

Moxalactam is not significantly susceptible to the majority of beta-lactamases produced by bacteria of clinical relevance. However, two types of enzyme--PSE2 and PSE3--from Pseudomonas aeruginosa can hydrolyze this antibiotic at a significant rate. In this respect moxalactam is similar to 7-alpha-methoxy cephem compounds, such as cefoxitin, which are also susceptible to these enzymes. Moxalactam, like other beta-lactam antibiotics having an acid function in the side chain, is a potent inhibitor of the cephalosporinase from Enterobacter cloacae (type Ia beta-lactamase).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218561     DOI: 10.1093/clinids/4.supplement_3.s522

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

1.  The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.

Authors:  S Srinivasan; E L Francke; C Ortiz-Neu; A S Prince; H C Neu
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

2.  Inactivation of cefoxitin and moxalactam by Bacteroides bivius beta-lactamase.

Authors:  F Malouin; C Fijalkowski; F Lamothe; J M Lacroix
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 3.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.